ArticleCell death & disease2026
ATP7A-mediated copper ion efflux reprogrammes tumour immunity and promotes cisplatin resistance in cervical cancer.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin resistance is a major obstacle to effective chemotherapy in patients with cervical cancer and is associated with an immunosuppressive tumour microenvironment. Copper ions are essential trace elements that regulate redox and immune balance. However, the connections among copper ions, cisplatin resistance and immune regulation remain unclear. Here, higher serum copper levels correlated with increased pan-cancer mortality. Integrative transcriptomic and single-cell RNA sequencing analyses revealed lower copper-related transcriptional activity in CD8⁺ T cells from cervical cancer tissues. Multiomics analysis revealed that ATPase copper transporting alpha (ATP7A) expression was upregulated in cisplatin-resistant patients compared with sensitive patients and correlated with poor survival. ATP7A knockdown increased sensitivity to cisplatin and promoted cuproptosis, whereas ATP7A overexpression increased cisplatin resistance and impaired CD8⁺ T cells through copper ion efflux. Furthermore, excess copper ions directly bind to the lymphocyte-specific protein tyrosine kinase (LCK) activation loop (Tyr394), impairing T-cell receptor (TCR) signalling in CD8⁺ T cells. Sex-determining region Y-box 21 (SOX21) directly binds two conserved motifs within the ATP7A promoter (-372 bp and -245 bp) and enhances its transcriptional activity. These results revealed a SOX21/ATP7A/copper ion axis connecting copper ion efflux with immune suppression and cisplatin resistance. Targeting ATP7A or copper ion efflux may restore CD8⁺T-cell activity and enhance the efficacy of cisplatin for the treatment of cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.